Skip to search formSkip to main contentSkip to account menu

14 ML pertuzumab 30 MG/ML Injection [Perjeta]

Known as: Perjeta 420 MG in 14 ML Injection, Perjeta 420 MG per 14 ML Injection, Pertuzumab 30 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [PERJETA] 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (2)

14 ML pertuzumab 30 MG/ML Injectionpertuzumab Injection [Perjeta]
Acetic AcidHistidineInjectionPerjeta

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter…
Background Previous trials showed that fixed-dose subcutaneous trastuzumab and hyaluronidase-oysk (Herceptin Hylecta™; H SC) was… 
2018
2018
PCN323 - PERJETA TREATMENT DURATION IN THE ITALIAN CLINICAL PRACTICE: A FIRST ANALYSIS OF THE AIFA PRESCRIPTION REGISTRY
2017
2017
HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes
BackgroundPertuzumab (Perjeta®), a HER2/neu receptor antagonist, was approved by the US Food and Drug Administration in June 2012… 
2017
2017
rrMM: Länger progressionsfrei durch Ixazomib
Als Late Breaker wurden anlässlich der ASCO-Jahrestagung erstmals Resultate der Phase-III-Studie APHINITY vorgestellt [von… 
Review
2015
Review
2015
Pertuzumab et T-DM1 : de nouvelles perspectives dans le traitement du cancer du sein HER2 positif
RésuméLe trastuzumab (Herceptine®, Roche) a complètement révolutionné le pronostic du cancer du sein HER2 positif, que ce soit en… 
Review
2014
Review
2014
Pertuzumab: development beyond breast cancer.
Pertuzumab (Perjeta®) represents the first monoclonal antibody in a new class of agents known as dimerization inhibitors… 
2014
2014
[Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Fifteen to 20% of breast cancers display HER2 amplification. Many therapeutic successes have been obtained for this subtype in… 
2014
2014
Abstract 109: PET imaging of 89Zr-labeled Pertuzumab in HER2-positive breast cancer xenografts
The sensitivity and quantitative properties of Positron Emission Tomography (PET) imaging combined with the selectivity and high… 
2013
2013
Pertuzumab kann Überlebenszeit bei Brustkrebs verlängern
Pertuzumab (Perjeta®) von Roche optimiert die gegen HER2 gerichtete Behandlung von Patientinnen mit metastasiertem HER2-positivem… 
Highly Cited
2013
Highly Cited
2013
Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration.
The physical/chemical stability and potential interactions after diluting two immunoglobulin G1 monoclonal antibodies (mAb… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)